Marwyn Value Investors vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Marwyn Value Investors (MVIR) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees Marwyn Value Investors as the more attractively valued of the two: Marwyn Value Investors trades at £2.83 versus a fair value of £5.66 (+100%), while Vertex Pharmaceuticals trades at $524 versus $279 (-47%).
Marwyn Value Investors
MVIR.LSE · GBP · Industrials
+100%
upside to fair value
undervalued
Price£2.83
Fair Value£5.66
Quality75/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-47%
upside to fair value
overvalued
Price$524
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Marwyn Value InvestorsVertex Pharmaceuticals
Valuation
4.1×P/E (TTM)28.8×
5.60×P/S (TTM)10.06×
1.46×P/B6.59×
5.6×EV/EBITDA23.8×
—PEG1.72×
Profitability
100%Net margin36%
100%Operating margin38%
29%Return on equity24%
18%Return on assets12%
Growth
135%Revenue growth (YoY)8%
166.1%Avg. growth/yr (3Y)10.6%
—Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$216MMarket cap$123B
mixedGrowth qualityhealthy
Marwyn Value Investors leads: 10 to 0 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Marwyn Value Investorsof which business quality 70 · market factors 68Vertex Pharmaceuticalsof which business quality 77 · market factors 77
ProfitabilityMargins and returns on capital today
69
72
Quality GrowthAre margins and returns improving?
80
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
56
58
Low VolatilityCalm price path (market factor)
100
85
MomentumPrice trend over the last 3–12 months (market factor)
48
67
52W MomentumDistance to the 52-week high (market factor)
67
86
Net IssuanceBuybacks instead of dilution
82
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Marwyn Value Investors
DCF Models£1,321
Earnings-Based£2,323
Multiples£1,071
Asset-Based£145
Growth DCF£144
Economic Profit£398
0 of 10 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
21 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Marwyn Value Investors
Bear £4.24Fair Value £5.66Bull £7.08
£2.83 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$524 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Marwyn Value Investors · Industrials
Quality score75 · Top 25%
Fair value upside+100% · Top 25%
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-47% · below median
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees Marwyn Value Investors as the more attractively valued of the two: Marwyn Value Investors trades at £2.83 versus a fair value of £5.66 (+100%), while Vertex Pharmaceuticals trades at $524 versus $279 (-47%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
